← Back to Clinical Trials
Recruiting NCT07536204

NCT07536204 Characterization of JAK1 and JAK2 Activation in Gingival Tissues During Homeostasis and Periodontitis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07536204
Status Recruiting
Phase
Sponsor University of Chile
Condition Periodontitis
Study Type OBSERVATIONAL
Enrollment 30 participants
Start Date 2023-06-01
Primary Completion 2027-03-31

Trial Parameters

Condition Periodontitis
Sponsor University of Chile
Study Type OBSERVATIONAL
Phase N/A
Enrollment 30
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-06-01
Completion 2027-03-31

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this observational study is to examine JAK1/2 pathway activation in gingival tissues from adults with healthy gingiva and those with inflamed gingiva (periodontitis). The main question it aims to answer is: Is the JAK1/2 pathway overactivated in periodontitis compared to health? Participants with healthy gingiva and periodontitis will donate gingival tissue to study the JAK1/2 pathway. All participants wil receive diagnosis and treatment of the gingival condition.

Eligibility Criteria

Inclusion Criteria: * Adults * Sistemically healthy Exclusion Criteria: * Active Maliganancy * History of radiation to the head-neck region * Chemotherapy or radiation within the last 5 years * History of hepatitis B/C or HIV infection * Autoimmune diseases * Diagnosis of diabetes * Pregnancy or lactation * More than 3 hospitalizations over the last 3 years * Use of systemic antibiotics over the last 3 months * Use of systemic corticosteroids or immunosuppressants over the last 3 months * Use of cytokine therapy over the last 3 months * Use of large doses of pre/probiotic supplements over the last 3 months * Smoke more than 10 cigarettes per day

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology